SAFETY UPDATE: Fosamprenavir (Telzir™)

By /

On February 19th, 2014 Health Canada issued an information update regarding labeling changes in the fosamprenavir (Telzir™) product monograph. The update includes a strengthened warning to avoid co-administration of fosamprenavir with certain medications used for regulating the rhythm of the heart. This labeling change does not represent a new safety concern.

For more information: Click here to view the Health Canada advisory

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search